Valeo Pharma Inc.

TSX:VPH Stock Report

Market Cap: CA$4.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Valeo Pharma Valuation

Is VPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VPH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VPH?

Key metric: As VPH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VPH. This is calculated by dividing VPH's market cap by their current revenue.
What is VPH's PS Ratio?
PS Ratio0.08x
SalesCA$53.38m
Market CapCA$4.44m

Price to Sales Ratio vs Peers

How does VPH's PS Ratio compare to its peers?

The above table shows the PS ratio for VPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.3x
CLC Christina Lake Cannabis
0.4xn/aCA$4.6m
CANB CanadaBis Capital
0.4xn/aCA$6.9m
XTRX Adastra Holdings
0.2xn/aCA$3.8m
AVNT Avant Brands
0.2xn/aCA$6.2m
VPH Valeo Pharma
0.08x20.9%CA$4.4m

Price-To-Sales vs Peers: VPH is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.3x).

Price to Sales Ratio vs Industry

How does VPH's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.0.8x10.6%
VPH Valeo Pharma
 0.08x20.9%US$3.18m
AYR.A Ayr Wellness
0.2x2.6%US$79.02m
TIUM.U Cansortium
0.2xn/aUS$27.19m
VPH 0.1xIndustry Avg. 0.8xNo. of Companies25PS012345+
25 CompaniesEstimated GrowthMarket Cap
Industry Avg.0.8x53.4%
VPH Valeo Pharma
 0.08xn/aUS$3.18m
No more companies

Price-To-Sales vs Industry: VPH is good value based on its Price-To-Sales Ratio (0.1x) compared to the Canadian Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is VPH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VPH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.08x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: VPH is good value based on its Price-To-Sales Ratio (0.1x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$127.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.59

7D

8.0%

1Y

-43.4%

Verano Holdings

CA$829.5m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.14

7D

-15.4%

1Y

-63.8%

Medexus Pharmaceuticals

CA$53.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.13

7D

4.9%

1Y

38.3%